Orthopediatrics outlines $270M-$273M 2026 revenue outlook while targeting $25M adjusted EBITDA and free cash flow breakeakeven or better

• "For the third quarter, we delivered record revenue of $72.7 million, up 19% over the prior year" (President, CEO & Director David Bailey), and "we are raising our full year revenue guidance to $270 million to $273 million, representing growth of 14% to 16%" (President Bailey).
• "We are extremely encouraged by the revenue contributions of our recent product launches, such as 3P Hip, Traxio and VerteGlide" (President Bailey), while emphasizing pacing: "we are being thoughtful with our set deployment strategy" and "bringing sets to market at a steady pace" (President Bailey).
• "Trauma and Deformity delivered revenue of $52.6 million, up 19%" (President Bailey), and OPSB "once again delivered an outstanding quarter with growth above 20%" (President Bailey), including Traxio demand: "we have already completely sold out of the initial limited units and are accelerating our 2027 build to meet the market demand" (President Bailey).
• "In scoliosis, global revenue increased 18% to $19.2 million" (President Bailey), and he framed 7D as not the driver: "we placed 170 unit this quarter compared with no units sold in the third quarter of 2025" and "it was not a major growth driver" (President Bailey).
• "Our third quarter of 2026 record revenue of $72.7 million increased 19% compared to $61.2 million in the third quarter of 2025" (CFO, Principal Financial & Accounting Officer, COO and Director Fred Hite), and "adjusted EBITDA was a record $6.9 million" with "an adjusted EBITDA margin of approximately 10%" (CFO Hite).

Outlook

• "We are raising our full year 2026 revenue guidance to be in the range of $270 million to $273 million" (CFO Hite) versus the prior quarter’s "raising our full year guidance to a range of $265 million to $269 million" (CFO Hite).
• "We're also reiterating our adjusted EBITDA guidance of approximately $25 million" (CFO Hite), and "we continue to expect to deploy approximately $10 million in sets and to achieve free cash flow breakeven or better in 2026 and beyond" (CFO Hite).
• On product ramp expectations, management indicated limited near-term contribution: "some of these products are not expected to contribute significant revenue in 2026" and "we expect a bigger growth opportunity to come in 2027 and beyond" (President Bailey).

Financial Results

• "U.S. revenue was $57.9 million" and "total international revenue was $14.8 million" (CFO Hite), with mix commentary that "international growth was underscored by robust European sales, partially offset by set sales timing in LatAm" (CFO Hite).
• Profitability and cost items included: "gross profit margin was 74%" (CFO Hite); "total operating expense was $58.2 million" (CFO Hite); and "intangible asset impairment was $0.6 million" (CFO Hite).
• Earnings and cash metrics included: "GAAP net loss per share for the period was $0.25" and "non-GAAP net loss per share for the period was $0.23" (CFO Hite); "free cash flow generated in the third quarter of 2026 was $1.6 million" (CFO Hite); and "we ended the third quarter with $45 million in cash, short-term investment and restricted cash" (CFO Hite).

Q&A

• Caitlin Roberts, Canaccord Genuity: asked where leverage comes from to hit EBITDA/FCF guidance; CFO Hite said Q3 commissions rose because "all 6 of our top partners, sales partners, distributors achieved quota" and "we will claw back some of that in the fourth quarter," adding "we need to generate $6 million of positive in the fourth quarter to get to the breakeven or better for the year" and "very, very confident that the free cash flow will absolutely get to breakeven or better for the year" (CFO Hite).
• Caitlin Roberts, Canaccord Genuity: asked about procedure environment; President Bailey responded, "We've had very healthy procedure volumes" and "we don't see anything that would put that in jeopardy heading into Q4 and as we move into 2027" (President Bailey).
• Frederick Wise, Stifel: questioned why Q4 guidance isn’t higher; President Bailey cited prior-year items, saying "in Q4 of last year, we had set sales to Brazil" and "we also did have pretty substantial 7D unit sales in Q4" and concluded "we're going to try to stay -- keep our guide in check" (President Bailey).
• Piper Sandler (Anna for Matt O’Brien): asked how the “Super Cycle” improves profitability; President Bailey said "It's a little bit of all of the above" and highlighted "higher ASP," that "these sets are more efficient" and "they return cash faster" (President Bailey).
• BTIG (Izzy for Ryan Zimmerman): asked about timing from limited to full launches; President Bailey said "3P Small and Mini" were "probably a first half to middle -- first half of next year type of story" for full release and PNP Retrograde is "probably a full market release sometime mid next year" (President Bailey).
• Michael Matson, Needham: asked about contracting impact; President Bailey said "the majority of our hospitals are on some form of contract" and described pushing toward "single vendor" or "high dual vendor" situations to drive "50%, 60%, 70%, maybe even 80% market share" and "pulls through some of those legacy sets" (President Bailey).
• Ravi Misra, Truist: asked about gross margin drivers and Q4; CFO Hite said "very pleased with the gross margin, 74%" and forecasted "73% is probably the right number for the fourth quarter" (CFO Hite), and added on OSSIO that "we really haven't contemplated OSSIO outside of the United States" (CFO Hite).

Sentiment Analysis

• Analysts were slightly positive and focused on durability of guidance and 2027 setup, pressing on conservatism (e.g., Stifel’s "Why couldn't that prove conservative" and "Help us think through" 2027 puts/takes).
• Management tone was positive in prepared remarks ("This was an outstanding quarter" (President Bailey)) and measured in Q&A, using caution around forecasting: "we are trying to make sure that we don't get ahead of ourselves" (President Bailey).
• Versus the prior quarter’s emphasis on an "inflection point" and confidence in "positive free cash flow in the second half of 2026" (President Bailey, Q2), Q3 added more explicit conservatism on Q4 variability tied to set sales and 7D (President Bailey).

Quarter-over-Quarter Comparison

• Guidance moved higher: Q3 raised 2026 revenue guidance to "$270 million to $273 million" (President Bailey) from Q2’s "$265 million to $269 million" (President Bailey), while adjusted EBITDA guidance remained "approximately $25 million" (CFO Hite in both quarters).
• Scoliosis shifted from Q2’s reported decline where "reported revenue was down 9%" (President Bailey, Q2) to Q3 growth where "global revenue increased 18% to $19.2 million" (President Bailey), with Q3 framing that underlying demand (not 7D) drove results.
• International growth moderated: Q3 reported "revenue increased 18% to $14.8 million" (President Bailey) versus Q2 "international revenue grew 22%" (President Bailey, Q2), with both quarters citing EU MDR-driven rollout as "early" (Q2) and "still in the early stages" (Q3).

Risks and Concerns

• Cash discipline remained a recurring constraint: "we are being judicious with how many sets we deploy at one time" (President Bailey), balancing "the need for growth against positive free cash flow" (President Bailey).
• LatAm receivables and set-sale timing continued to be managed: management described "headwinds from lower set sales" (President Bailey) and said it would be "very smart and very conservative" in markets where it "don't want to have the larger AR balances" (President Bailey).

Final Takeaway

Management described Q3 as a record quarter with raised 2026 revenue guidance, reiterated adjusted EBITDA targets, and a continued commitment to disciplined set deployment and free-cash-flow execution. Leadership emphasized that newer products are contributing but still early in adoption, and positioned 2027 as the period where a broader set of full launches and wider utilization could expand growth, margin, and capital efficiency, while maintaining a conservative posture around timing-dependent items such as set sales and 7D unit placements.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.